SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
Adolescent
Adult
Antibodies, Neutralizing
/ administration & dosage
Antibodies, Viral
/ administration & dosage
Antibody Affinity
Blood Donors
COVID-19
/ therapy
Cohort Studies
Cross-Sectional Studies
Female
Humans
Immunization, Passive
Immunoglobulin G
/ administration & dosage
Linear Models
Male
Middle Aged
SARS-CoV-2
Spike Glycoprotein, Coronavirus
/ immunology
Young Adult
COVID-19 Serotherapy
SARS-CoV-2
anti-nucleocapsid
anti-spike
avidity
convalescent plasma
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
13 11 2020
13 11 2020
Historique:
received:
22
07
2020
accepted:
08
09
2020
pubmed:
11
9
2020
medline:
22
12
2020
entrez:
10
9
2020
Statut:
ppublish
Résumé
Convalescent plasma therapy is a leading treatment for conferring temporary immunity to COVID-19-susceptible individuals or for use as post-exposure prophylaxis. However, not all recovered patients develop adequate antibody titers for donation and the relationship between avidity and neutralizing titers is currently not well understood. SARS-CoV-2 anti-spike and anti-nucleocapsid IgG titers and avidity were measured in a longitudinal cohort of COVID-19 hospitalized patients (n = 16 individuals) and a cross-sectional sample of convalescent plasma donors (n = 130). Epidemiologic correlates of avidity were examined in donors by linear regression. The association of avidity and a high neutralizing titer (NT) were also assessed in donors using modified Poisson regression. Antibody avidity increased over duration of infection and remained elevated. In convalescent plasma donors, higher levels of anti-spike avidity were associated with older age, male sex, and hospitalization. Higher NTs had a stronger positive correlation with anti-spike IgG avidity (Spearman ρ = 0.386; P < .001) than with anti-nucleocapsid IgG avidity (Spearman ρ = 0.211; P = .026). Increasing levels of anti-spike IgG avidity were associated with high NT (≥160) (adjusted prevalence ratio = 1.58 [95% confidence interval = 1.19-2.12]), independent of age, sex, and hospitalization. SARS-CoV-2 antibody avidity correlated with duration of infection and higher neutralizing titers, suggesting a potential alternative screening parameter for identifying optimal convalescent plasma donors.
Sections du résumé
BACKGROUND
Convalescent plasma therapy is a leading treatment for conferring temporary immunity to COVID-19-susceptible individuals or for use as post-exposure prophylaxis. However, not all recovered patients develop adequate antibody titers for donation and the relationship between avidity and neutralizing titers is currently not well understood.
METHODS
SARS-CoV-2 anti-spike and anti-nucleocapsid IgG titers and avidity were measured in a longitudinal cohort of COVID-19 hospitalized patients (n = 16 individuals) and a cross-sectional sample of convalescent plasma donors (n = 130). Epidemiologic correlates of avidity were examined in donors by linear regression. The association of avidity and a high neutralizing titer (NT) were also assessed in donors using modified Poisson regression.
RESULTS
Antibody avidity increased over duration of infection and remained elevated. In convalescent plasma donors, higher levels of anti-spike avidity were associated with older age, male sex, and hospitalization. Higher NTs had a stronger positive correlation with anti-spike IgG avidity (Spearman ρ = 0.386; P < .001) than with anti-nucleocapsid IgG avidity (Spearman ρ = 0.211; P = .026). Increasing levels of anti-spike IgG avidity were associated with high NT (≥160) (adjusted prevalence ratio = 1.58 [95% confidence interval = 1.19-2.12]), independent of age, sex, and hospitalization.
CONCLUSIONS
SARS-CoV-2 antibody avidity correlated with duration of infection and higher neutralizing titers, suggesting a potential alternative screening parameter for identifying optimal convalescent plasma donors.
Identifiants
pubmed: 32910175
pii: 5903688
doi: 10.1093/infdis/jiaa581
pmc: PMC7499592
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin G
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1974-1984Subventions
Organisme : NIAID NIH HHS
ID : R01 AI152078
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI095068
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI120938
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL059842
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068613
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI128779
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI102623
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI052733
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL151826
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
J Clin Invest. 2020 Jun 1;130(6):2757-2765
pubmed: 32254064
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Ann Hematol. 2020 Sep;99(9):2113-2118
pubmed: 32656591
Clin Vaccine Immunol. 2007 Nov;14(11):1433-6
pubmed: 17881505
Cell Mol Immunol. 2020 Jun;17(6):613-620
pubmed: 32203189
Intensive Care Med. 2020 Jul;46(7):1472-1474
pubmed: 32328724
Virology. 2008 Oct 25;380(2):312-21
pubmed: 18760437
J Med Virol. 2021 Feb;93(2):1141-1144
pubmed: 32706420
Microbiol Mol Biol Rev. 2016 Oct 26;80(4):989-1010
pubmed: 27784796
J Clin Invest. 2020 Sep 1;130(9):4791-4797
pubmed: 32525844
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32277023
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Blood. 2020 Aug 6;136(6):652-654
pubmed: 32761223
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
J Clin Microbiol. 2005 Dec;43(12):5873-5
pubmed: 16333069
Virus Res. 2014 Dec 19;194:175-83
pubmed: 24670324
J Clin Microbiol. 2001 Nov;39(11):4152-4
pubmed: 11682546
Int J Biol Sci. 2020 Mar 15;16(10):1718-1723
pubmed: 32226289
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
J Infect Dis. 2005 Jul 1;192(1):166-9
pubmed: 15942907
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Adv Biol. 2014;2014:
pubmed: 27099867
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652
J Clin Microbiol. 2007 Feb;45(2):415-20
pubmed: 17151211